PTC Therapeutics, Inc. (NASDAQ:PTCT) has been given an average rating of “Buy” by the thirteen analysts that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $56.00.

PTCT has been the subject of several recent research reports. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 30th. ValuEngine raised shares of PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Citigroup dropped their price target on shares of PTC Therapeutics from $62.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Credit Suisse Group increased their price target on shares of PTC Therapeutics from $54.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday.

Shares of NASDAQ PTCT traded down $0.28 during mid-day trading on Monday, hitting $42.72. The company had a trading volume of 535,500 shares, compared to its average volume of 739,818. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.40 and a quick ratio of 4.30. The business’s 50-day simple moving average is $37.50 and its 200-day simple moving average is $41.22. PTC Therapeutics has a 12 month low of $27.53 and a 12 month high of $48.81. The firm has a market cap of $2.55 billion, a P/E ratio of -23.22 and a beta of 1.88.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by ($0.15). PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The company had revenue of $71.40 million during the quarter, compared to the consensus estimate of $72.03 million. During the same quarter in the previous year, the business posted ($1.06) EPS. The firm’s quarterly revenue was up 33.2% on a year-over-year basis. As a group, sell-side analysts predict that PTC Therapeutics will post -2.68 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Boston Advisors LLC increased its holdings in shares of PTC Therapeutics by 42.3% during the third quarter. Boston Advisors LLC now owns 38,641 shares of the biopharmaceutical company’s stock worth $1,307,000 after buying an additional 11,479 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of PTC Therapeutics during the third quarter worth approximately $130,000. First Trust Advisors LP increased its holdings in shares of PTC Therapeutics by 54.4% during the third quarter. First Trust Advisors LP now owns 49,459 shares of the biopharmaceutical company’s stock worth $1,673,000 after buying an additional 17,429 shares in the last quarter. Mackay Shields LLC increased its holdings in shares of PTC Therapeutics by 2.7% during the third quarter. Mackay Shields LLC now owns 49,610 shares of the biopharmaceutical company’s stock worth $1,678,000 after buying an additional 1,300 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of PTC Therapeutics by 513.3% during the third quarter. Russell Investments Group Ltd. now owns 58,401 shares of the biopharmaceutical company’s stock worth $1,975,000 after buying an additional 48,879 shares in the last quarter. 93.65% of the stock is owned by institutional investors.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Featured Story: What is an investor looking for in an SEC filing?

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.